stocks1

Weekly Movers: Neuren Pharma, Eli Lilly, Gilead Sciences…

May 3, 2016
Manufacturing and Production

Corporate result announcements remained the key focus as well as the primary drivers for stock movements this week as the …

regeneron

Regeneron says trial drug for osteoarthritis pain meets primary endpoint in Phase II trials

May 3, 2016
Manufacturing and Production, Research and Development Phase II, Regeneron Pharmaceuticals, drug trial, osteoarthritis, phase III

Regeneron Pharmaceuticals (Nasdaq: REGN) said mid-stage trials for its drug candidate to treat osteoarthritis pain med its primary endpoint. The …

bill_ackman

Big investor hits back at critics as Valeant’s war of words gathers pace

May 3, 2016
Manufacturing and Production, Sales and Marketing Valeant, ackman, allegations, buffett, practices, price gouging, price rises, scandal

Valeant have hit the mainstream news again after key investor Bill Ackman mounted a robust defence of the company, ruling …

v2_crestor_10_mg

Allergan launches Crestor generic in the US

May 3, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Allergan, AstraZeneca, Crestor, FDA, FDA Approval, cholesterol, generic, patent, patent expiry, sales

Allergan has received FDA approval on the generic version of AstraZeneca’s high cholesterol drug, Crestor (rosuvastatin), and has become the …

mylan_building

Mylan Q1 revenue up 17%, maintains FY view

May 3, 2016
Manufacturing and Production, Sales and Marketing Financial, Mylan, Q1, results, revenue, sales

Pharma firm Mylan NV (Nasdaq: MYL) on Tuesday reported a 17% rise in first-quarter revenue and said it maintains its …

novartis_afinitor

Afinitor receives EU recommendation to treat rare lung cancer

April 29, 2016
Manufacturing and Production, Research and Development, Sales and Marketing Afinitor, Novartis

Novartis has received a recommendation from the Committee for Medicinal Products for Human Use at the European Medicines Agency for …

sanofi_hq__boetie_hall

Board at Medivation unanimously reject Sanofi bid

April 29, 2016
Medical Communications, Sales and Marketing Medivation, Sanofi, board, hostile, rejection, takeover

The board at Medivation has unanimously rejected the $9.8 billion takeover bid from Sanofi. They declare that Sanofi’s bid of …

novartis_horsham_site_closure

Novartis’ two cancer drugs get NICE backing as combination treatment for skin cancer

April 29, 2016
Medical Communications NICE, Novartis, combination therapy, regulation, skin cancer

The National Institute for Health and Care Excellence (NICE) on Friday backed a combination therapy for skin cancer comprising two …

novo_nordisk_flag

Novo Nordisk Q1 operating profit down 10% in local currencies

April 29, 2016
Medical Communications, Sales and Marketing Financial, Novo Nordisk, Q1, earnings, outlook, results

Denmark’s Novo Nordisk (NYSE: NOV) on Friday posted a 10% drop in first-quarter operating profit and said it maintains its full year …

sanofi_hq__boetie_hall

Sanofi confirm 2016 outlook with Q1 results, EPS rises 5.3%

April 29, 2016
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 2016, Q1, Sanofi, earnings, outlook, results

Sanofi (EPA: SAN) has confirmed its outlook for 2016 with the publication of their first quarter results, with earnings per …

astrazeneca_sign_sky

AstraZeneca Q1 earnings down 12%; maintains FY view

April 29, 2016
Medical Communications, Research and Development, Sales and Marketing AstraZeneca, Q!, earnings, outlook, profits, q, results

UK drugmaker AstraZeneca (LSE: AZN) on Friday reported a 12% drop in first-quarter earnings and said it plans to streamline …

amgen_hq

Amgen raises 2016 outlook after Q1 earnings boost

April 29, 2016
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, Enbrel, etanercept, financial results, financials, sales rise

Amgen (NASDAQ: AMGN) has upgraded their 2016 outlook after posting an increase of 10% in revenues for the first quarter …

abbvie_0

AbbVie expands oncology portfolio with $5.8 billion Stemcentrx acquisition

April 29, 2016
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AbbVie, acquisition, rova-t, stremcentrx, takeover

AbbVie (NYSE: ABBV) has announced the acquisition of Stemcentrx, and its lead late stage, lung cancer candidate Rova-T (rovalpituzumab tesirine), …

The mutual benefit of becoming one of Britain’s best workplaces

April 28, 2016
Medical Communications great place to work, medical communications, medical communications agency

Imagine a company with a 100%-satisfied workforce. What could a team of such fulfilled employees really deliver to clients?

abbottweb

Abbott to purchase St Jude Medical in $25 billion deal

April 28, 2016
Manufacturing and Production, Research and Development, Sales and Marketing $25, 25 billion, Abbott, Medical device, acquisition, purchase, st jude medical

Abbott (NYSE: ABT) has announced an agreement to purchase device manufacturer, St Jude Medical, in a deal worth $25 billion. …

affordability

World Immunisation Week marked by ABPI reception in House of Commons

April 28, 2016
Medical Communications ABPI, immunisations

The ABPI vaccine group joined a host of figures at a parliamentary reception to mark World Immunisation Week. Parliamentarians, policy …

sobi

Sobi profits rise as it rolls out haemophilia drug in Europe

April 28, 2016
Financial, Q1, earnings, results, revenue, sobi

Swedish Orphan Biovitrum (Sobi) (STO: SOBI) nearly doubled its first-quarter profit driven by immediate reimbursements from Germany. The company reported …

j

Valeant’s outgoing boss tells Senate committee he “regrets” drug price rises

April 28, 2016
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Senate, Valeant, admits, aggressive, committee, drug price, pearson, rises

Outgoing Valeant (NYSE: VRX) boss, Michael Pearson, expressed regret at the way his company conducted operations to a US Senate …

tuyen_ong

PTC Therapeutics appoints Tuyen Ong as chief medical officer

April 28, 2016
Business Services, Research and Development

PTC Therapeutics (Nasdaq: PTCT) has named Tuyen Ong chief medical officer.  He succeeds Robert Spiegel who will remain with the company …

pfizer_finland_hq

Pfizer to pay $784.6 million fine due to Wyeth Medicaid fraud

April 28, 2016
Medical Communications, Sales and Marketing False Claims Act, Medicaid, Pfizer, US, Wyeth, department, fraud, insurer, justice

Pfizer has agreed to pay $784.6 million in a settlement with the US Department of Justice, relating to false and …

The Gateway to Local Adoption Series

Latest content